Skip To Main Content
Shao-Ying Yang on Muck Rack

Shao-Ying Yang

As seen in: Nature, Wiley Online Library, MDPI, Science Magazine, The Journal of Clinical Investigation
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Shao-Ying

Contact Shao-Ying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Enzymatic activity-independent NANS stabilizes LATS2 to drive growth and therapeutic resistance in HR+/HER2- breast cancer

|
By Jia-Yang Cai, Min-Ying Huang, Shao-Ying Yang, Fang-Lin Zhang, Yin-Ling Zhang, Lisa Andriani, Qian Zhao, Da-Qiang Li, Zhi-Ming Shao, A-Yong Cao
| Nature Verified
Abstract Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+ /HER2-) breast cancer is the most common subtype in females, frequently challenged by resistance to endocrine therapy and CDK4/6 inhibitors. Here we show that N-acetylneuraminate synthase (NANS) is significantly upregulated in female HR+ /HER2- breast cancer patients, inversely correlating with patient prognosis.
Open in Who Shared Issue with article?

MYC/TET3‐Regulated TMEM65 Activates OXPHOS‐SERPINB3 Pathway to Promote Progression and Cisplatin Resistance in Triple‐Negative Breast Cancer

|
By Yin-Ling Zhang, Min-Ying Huang, Shao-Ying Yang, Jia-Yang Cai
| Wiley Online Library Verified
1 Introduction Triple-negative breast cancer (TNBC) is a specific subtype of breast cancer, which lacks the expression of estrogen and progesterone receptors and human epidermal growth factor receptor 2 (HER2) and accounts for about 15% of all breast cancer cases.[1] Clinically, TNBC exhibits aggressively clinicopathological features with a high incidence of early recurrence and distant metastases and the worst outcomes.[1] Due to the absence of validated therapeutic targets, chemotherapy is...
Open in Who Shared Issue with article?

Kinesin-like protein KIFC2 stabilizes CDK4 to accelerate growth and confer resistance in HR+/HER2- breast cancer

|
By Shao-Ying Yang, Ming-Liang Jin, Lisa Andriani, Qian Zhao
| The Journal of Clinical Investigation
ResearchCell biologyOncology Open Access | 10.1172/JCI183531 J Clin Invest. https://doi.org/10.1172/JCI183531. Copyright © 2025, Yang et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Open in Who Shared Issue with article?
See all 5 articles